Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.67 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41893 | 0.84 | ACHE (0.48) | ACHEIDO1CYP3A4TSHRTDP1 | |
| SCHEMBL112048 | 0.84 | ACHE (0.48) | ACHEIDO1CYP3A4TSHRTDP1 | |
| SCHEMBL6542413 | 0.81 | CA2 (0.44) | ACHEIDO1CYP3A4TSHRTDP1 | |
| SCHEMBL248195 | 0.81 | ACHE (1.00) | ACHECYP3A4TSHRKDM4ECASP6 | |
| SCHEMBL351788 | 0.81 | ACHE (0.88) | ACHECYP3A4TSHRKDM4ECASP6 | |
| SCHEMBL4469238 | 0.80 | ACHE (0.40) | ACHEIDO1CYP3A4TSHRTDP1 | |
| SCHEMBL24264540 | 0.78 | IDO1 (0.46) | ACHEIDO1CYP3A4TSHRTDP1 | |
| SCHEMBL3987382 | 0.78 | PTGS2 (0.40) | ACHEIDO1CYP3A4TSHRTDP1 | |
| SCHEMBL12811988 | 0.78 | ACHE (0.39) | ACHEIDO1CYP3A4TSHRTDP1 | |
| SCHEMBL28742800 | 0.76 | LTA4H (0.41) | ACHEIDO1CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745136-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITOR, COMPOSITION COMPRISING SAME, AND MEDICAL USE THEREOF | Shenzhen Zhongge Biological Technology Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025011570-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITOR, COMPOSITION COMPRISING SAME, AND MEDICAL USE THEREOF | 深圳众格生物科技有限公司 | 2025-01-16 | — | — | WO | disclosed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
| WO-2019189778-A1 | COMPOUND WITH ANTICANCER ACTIVITY | 協和発酵キリン株式会社 | 2019-10-03 | — | — | WO | disclosed |
| CN-101595102-B | Diaryl ether urea compounds | PFIZER PROD INC | 2013-08-07 | — | — | CN | disclosed |
| CN-102348674-A | Leukotriene b4 inhibitors | HOFFMANN LA ROCHE | 2012-02-08 | — | — | CN | disclosed |
| EP-2411358-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010108856-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010108856-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2010-09-23 | — | — | US | disclosed |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2010-09-23 | — | — | US | disclosed |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2010-09-23 | — | — | US | disclosed |
| CN-101595102-A | Diaryl ether urea compounds | PFIZER PROD INC (US) | 2009-12-02 | — | — | CN | disclosed |
| EP-2076508-A2 | BIARYL ETHER UREA COMPOUNDS | Pfizer Products Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2009067493-A2 | 1,3,5 TRI-SUBTITUTED BENZENES FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISORDERS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20080261941-A1 | Biaryl Ether Urea Compounds | Jazz Pharmaceuticals Therapeutics, Inc. | 2008-10-23 | — | — | US | disclosed |
| WO-2008047229-A2 | BIARYL ETHER UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | ACHE 1310/4885IDO1 207/4885CYP3A4 38/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | ACHE 1310/4885IDO1 207/4885CYP3A4 38/4885 |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | ACHE 1901/4885IDO1 1245/4885CYP3A4 402/4885 |
| US-20080261941-A1 | Biaryl Ether Urea Compounds | FAAH, FAAH2, LIPC | ACHE 879/4885IDO1 1021/4885CYP3A4 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.